-
With a stocked late-stage pipeline, Astellas has turned its attention to growing its early-stage pipeline with a focus on external partnerships over traditional bricks-and-mortar R&D.
Published on 6/17/2013
-
Externalizing Astellas Building the Astellas pipeline Astellas Pharma Inc. (Tokyo:4503) has relied heavily on in-licensing and acquisitions to stock its clinical-stage pipeline, with 15 of its 22 Phase III/…
Published on 6/17/2013
-
Amgen has had a development foothold in Japan for decades, but its new JV with Astellas will give the biotech its first commercial presence in the country.
Published on 6/17/2013
-
Merck Serono is bringing Quintiles to the table for clinical strategy, protocol design and execution of the specialty pharma's Phase I-IV trials. The goal is shorter, cheaper trials with higher success rates.
Published on 6/10/2013
-
At least one PBM believes oral MS drugs have entered the market at the right price relative to their injectible competition; long-term outcomes data could boost the orals on formularies
Published on 6/10/2013
-
Taiho has embarked on a five-year plan to expand into Western markets using two chemotherapeutics as late-stage beachheads for its early stage pipeline of innovative small molecules.
Published on 6/3/2013
-
Taiho goes global Taiho's cancer pipeline Taiho Pharmaceutical Co. Ltd.'s cancer pipeline consists of both chemotherapeutics and targeted therapies, along with programs in-licensed specifically for the Japanese and/…
Published on 6/3/2013
-
If Elan is able to fend off Royalty Pharma's latest offer at a June shareholder meeting, the company will reinvent itself as a royalty-backed business with a small late-stage pipeline.
Published on 5/27/2013
-
Raptor is launching an ultra-Orphan drug it has shown is non-inferior to a cheaper alternative without having payers on board with the $250,000 price. It is banking on quality of life gains from better compliance.
Published on 5/20/2013
-
Shire is paying collaborators to propose their best ideas for innovation in rare diseases, and is applying a similar open mind in its investment partnership with Atlas Ventures.
Published on 5/20/2013
-
Let a thousand ideas bloom Shire's rare deals Shire plc (LSE:SHP; NASDAQ:SHPG) has done at least 12 early stage and discovery deals in the Orphan and rare disease space since 2008. The range of deal structures gives…
Published on 5/20/2013
-
Shire's new CEO is consolidating R&D with the goal of broadening the company's reach in specialty pharma.
Published on 5/20/2013
-
Doubling down in diabetes Merck's diabetes deals Merck & Co. Inc. has signed at least 12 diabetes-related deals since the pharma and Bristol-Myers Squibb Co. terminated a co-development deal for BMS's Pargluva …
Published on 5/6/2013
-
As sales flatten for Merck's sitagliptin franchise and a new class of oral diabetes drugs comes to market, the pharma has tapped Pfizer and Abide to shore up its position.
Published on 5/6/2013
-
Celgene has identified protein homeostasis as the next area of breakthrough science where it wants to place a large bet, and has put its chips on Forma's discovery platform.
Published on 5/6/2013
-
By creating a global specialty medicines unit, Teva aims to accelerate worldwide launches of branded innovator drugs for itself, as well as for partners who don't command Teva's strong commercial footprint.
Published on 4/29/2013
-
Two years into the job at Sanofi, Elias Zerhouni has shaken up the company's R&D structure, dumped programs and reoriented toward disease biology. But he says the real evidence of change won't come until 2016.
Published on 4/29/2013
-
Zerhouni's progress report Sanofi then & now Since he began his strategic review in early 2009, Elias Zerhouni, head of global R&D at Sanofi (Euronext:SAN; NYSE:SNY), has focused on advancing programs with novel …
Published on 4/29/2013
-
Zerhouni's progress report Sanofi's discontinued programs Sanofi (Euronext:SAN; NYSE:SNY) is no longer purusing 19 of the 27 NMEs that were in Phase II or Phase III/registration at the start of 2009. Some of the …
Published on 4/29/2013
-
With the most stocked clinical pipeline among its RNAi peers, Alnylam has made the leap from platform to products, providing a case study for the use of IP for company building and sustainable finance.
Published on 4/15/2013
-
IP armamentarium Alnylam chronicles With so many of its early years devoted to figuring out RNAi delivery, Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) had to depend on its investors, who weren't always patient, …
Published on 4/15/2013
-
IP armamentarium Dealing in RNAi As it transitions from a pure platform play to a product company, Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) continues to do deals for its RNAi technology as well as partnerships for…
Published on 4/15/2013
-
AstraZeneca's reset AstraZeneca's pipeline fast track AstraZeneca plc (LSE:AZN; NYSE:AZN) has prioritized six therapeutics to be advanced into Phase III or pivotal testing as fast as possible. Of the six, four are …
Published on 4/8/2013
-
Following a spending spree for late-stage assets in 2012, AZ believes its Phase II/III pipeline now can restore long-term growth on the back of a revamped commercial strategy in emerging markets and Japan.
Published on 4/8/2013
-
With two deals in as many weeks, Shire has set its sights on ophthalmics as its next specialty play. Similar deals could be in the offing, according to incoming CEO Flemming Ornskov.
Published on 4/1/2013